Given the therapeutic relevance of targeting BCMA in MM, several groups have generated dual CAR targeting BCMA and other antigens of interest, such as MICA/MICB or GPRC5D, to address the efficacy limitations of CAR-T (31–33). Here, TNFRSF17 is linked to Miyoshi myopathy.